Global Data and Israeli Experts Warn of Dramatic Rise in Prostate Cancer Cases

Global health data reveals a dramatic rise in prostate cancer diagnoses and fatalities, with new U.S. guidelines recommending earlier screenings as Israeli experts report similar upward trends.

Global Data and Israeli Experts Warn of Dramatic Rise in Prostate Cancer Cases
Photo-illustration WireIsrael: AI Generated

Global and domestic health data reveal a dramatic rise in prostate cancer diagnoses and fatalities, prompting leading oncologists to warn of a growing public health crisis. According to figures from the Global Cancer Observatory of the International Agency for Research on Cancer under the World Health Organization, more than 1.5 million men worldwide were diagnosed with the disease in 2024, with projections indicating that new cases could nearly double by 2040.

Dr. Sternberg, head of the urological oncology unit at the Emek Medical Center within the Clalit Health Services group, noted that worldwide deaths have already surpassed 400,000 annually. Projections suggest that annual new cases could reach nearly three million, while fatalities may exceed 700,000 by 2040.

Rising Incidence and Delayed Diagnoses in Israel

Israel reflects this global upward trend. Data from the National Center for Disease Control at the Ministry of Health show that incidence rates among Jewish men rose by an annual average of approximately 3.8% between 2015 and 2022. Furthermore, estimates published by the Israel Cancer Association indicate that by the end of 2026, roughly 3,725 Israeli men will be diagnosed, and about 538 are expected to die from the disease.

Dr. Sternberg emphasized that medical professionals are observing more advanced cases among younger patients, particularly in peripheral regions where individuals often skip routine screenings. He attributed the surge to a combination of true epidemiological increases driven by rising life expectancy and family genetic mutations, alongside expanded screening practices that detect more tumors.

New Early Detection Guidelines and Treatment Landscape

In response to these trends, the American Cancer Society issued updated guidelines for early detection, recommending regular prostate-specific antigen testing every two years for average-risk men aged 50 to 69, and starting at age 45 for those at elevated risk.

"For years, the American approach to prostate cancer screening was conservative due to concerns over overdiagnosis and procedural risks," Dr. Sternberg explained. "Now we are seeing a significant shift in approach. This is a massive change, practically an earthquake. We are seeing not only more patients, but also more individuals dying from the disease, sometimes diagnosed when it is no longer curable."

Despite the alarming statistics, Dr. Sternberg stressed that Israel remains at the global forefront of prostate cancer diagnostics and treatment, possessing advanced clinical tools. However, he cautioned that a substantial portion of these cutting-edge technologies remains outside the public health basket, limiting equal access for all patients and highlighting the need for broader state funding.

Related News